IP Library Granted Patent US 12,264,174
Granted Patent B2
US 12,264,174 · App. 18/435,848 · Granted Apr 1, 2025

Process for preparing imetelstat

Inventors: Jale Muslehiddinoglu (Beerse, BE); Dinesh Gala (Beerse, BE); Jennifer Elizabeth Albaneze-Walker (Beerse, BE)
Assignee: Geron Corporation
C07H1/00C07H21/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,264,174
App. No.
18/435,848
Granted
Apr 1, 2025
Kind
B2
Abstract

The present invention relates to a process for preparing the telomerase inhibitor imetelstat using a 3 steps per cycle solid-phase support bound process comprising the steps of deprotection of the 3′-amino group of the support-bound oligonucleotide, coupling with a 5′-phosphoramidite, and sulfurization with an acyl disulfide, characterized by the absence of an additional capping step in each cycle that is used to prevent unreacted 3′-amino oligonucleotide groups from reacting during subsequent cycles. Imetelstat has formula below.

Claims (22)

1. A method of synthesizing the N3′→P5′ thiophosphoramidate oligonucleotide imetelstat of formula imetelstat

the method comprising:

a) providing a first 3′-amino protected nucleotide attached to a solid-phase support of formula (A) wherein PG is an acid-labile protecting group;

b) deprotecting the protected 3′-amino group to form a free 3′-amino group;

c) reacting the free 3′-amino group with a protected 3′-aminonucleoside-5′-O-cyanoethyl-N,N-diisopropylaminophosphoramidite monomer of formula (B′ n ), wherein B′ n with n=2 is protected A, to form an internucleoside N3′→P5′-phosphoramidite linkage;

d) sulfurization of the internucleoside phosphoramidite group using an acyl disulfide to form a N3′→P5′ thiophosphoramidate;

e) repeating 11 times in successive order the deprotection step b), the coupling step c) with a protected 3′-aminonucleoside-5′-O-cyanoethyl-N,N-diisopropylamino-phosphoramidite monomer of formula (B′ n ) wherein the nucleoside base B′ of monomer (B′ n ) is protected B except when B is thymine, and wherein B n is successively nucleobase B 3 to B 13 in the respective 11 coupling steps, and the sulfurization step d);

f) removing the acid-labile protecting group PG; and

g) deprotecting and cleaving imetelstat from the solid-phase support;

characterized in that no additional capping step is performed in any of the reaction steps a) to e).

2. The method as claimed in claim 1 , wherein imetelstat is further converted into its sodium salt.

3. The method as claimed in claim 1 , wherein the acyl disulfide is selected from dibenzoyl disulphide, bis(phenylacetyl) disulfide (PADS), bis(4-methoxybenzoyl) disulphide, bis(4-methylbenzoyl) disulphide, bis(4-nitrobenzoyl) disulphide and bis(4-chlorobenzoyl) disulfide.

4. The method as claimed in claim 3 , wherein the acyl disulfide is PADS.

5. The method as claimed in claim 4 , wherein PADS is dissolved in a mixture of 3-picoline or 2,6-lutidine with a co-solvent selected from acetonitrile, toluene, 1-methylpyrrolidinone and tetrahydrofuran.

6. The method as claimed in claim 5 , wherein PADS is dissolved in a mixture of 2,6-lutidine with acetonitrile.

7. The method as claimed in claim 6 , wherein the PADS solution is aged between 4 and 14 hours before use.

8. The method as claimed in claim 1 , wherein the acid-labile group PG is selected from triphenylmethyl, p-anisyldiphenylmethyl, and di-p-anisylphenylmethyl.

9. The method as claimed in claim 1 , wherein the acid-labile protecting group PG is removed by treatment with an acidic solution.

10. The method as claimed in claim 1 , wherein the base-labile protecting group on an adenine, cytosine and guanine base in the monomer of formula (B′ n ) is selected from acetyl, benzoyl, isobutyryl, dimethylformamidinyl, and dibenzylformamidinyl.

11. The method as claimed in claim 1 , wherein the coupling step c) is performed using an activator selected from tetrazole, 5-(ethylthio)-1H-tetrazole, 5-(4-nitro-phenyl) tetrazole, 5-(2-thienyl)-1H-tetrazole, triazole, and pyridinium chloride.

12. The method as claimed in claim 1 , wherein step g) is performed by treatment with a basic solution.

13. The method as claimed in claim 12 , wherein the basic solution is diethylamine dissolved in acetonitrile or aqueous ammonia dissolved in an alcohol, or a combination of both.

Assignments (5)
PATENT SECURITY AGREEMENT Recorded Aug 22, 2025
From: GERON CORPORATION
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 072558/0246 →
PATENT SECURITY AGREEMENT Recorded Nov 12, 2024
From: GERON CORPORATION
To: BIOPHARMA CREDIT PLC [COLLATERAL AGENT]
Reel/Frame 069341/0832 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE NAME OF THE ASSIGNEE PREVIOUSLY RECORDED AT REEL: 67615 FRAME: 208. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 6, 2024
From: MUSLEHIDDINOGLU, JALE; GALA, DINESH; ALBANEZE-WALKER, JENNIFER E.
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 068232/0676 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2024
From: MUSLEHIDDINOGLU, JALE; GALA, DINESH; ALBANEZE-WALKER, JENNIFER E.
To: JANSSEN PHARMACEUTICA NC
Reel/Frame 067615/0208 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2024
From: JANSSEN PHARMACEUTICA NV
To: GERON CORPORATION
Reel/Frame 067615/0287 →
Priority Claims (1)
EP 17180426 · Jul 10, 2017 · regional
Continuity (5)
Continuation 18487919 · Oct 16, 2023
Continuation 17979311 · Nov 2, 2022
Continuation 17718990 · Apr 12, 2022
Continuation 16623984
Related Publication 20240262854A1 · Aug 8, 2024
References Cited (13)
US 7494982B2 · Gryaznov et al. · 2009 [cited by applicant]
US 8980853B2 · Bennett et al. · 2015 [cited by applicant]
WO 2001018015 · 2001 [cited by applicant]
WO 2005023994 · 2005 [cited by applicant]
WO WO2005023994A2 · 2005 [cited by examiner]
WO 2006014387 · 2006 [cited by applicant]
WO 2015168310 · 2015 [cited by applicant]
WO 2017223258 · 2017 [cited by applicant]
Herbert, et al., (2005), “Lipid modification of GRN163, an N3′ → P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition”, Oncogene, 24:5262-5268. [cited by applicant]
Horie et al., (2005) “Synthesis and properties of ENA oligonucleotides targeted to human telomerase RNA subunit”, Nucleic Acids Symposium Series, 49(1):171-172. [cited by applicant]
Jensen et al., (2018) “Template-Independent Enzymatic Oligonucleotide Synthesis (TiEOS): Its History, Prospects, and Challenges”, Biochemistry, 57(12):1821-1832. [cited by applicant]
Lee et al., (2010), “A microfluidic oligonucleotide synthesizer”, Nucleic Acids Research, 38(8):1-8. [cited by applicant]
Scotson et al., (2016), “Phosphorothioate anti-sense oligonucleotides: the kinetics and mechanism of the sulfurisation of phosphites by phenylacetyl disulfide (PADS).”, Organic & Biomolecular Chemistry, 14(46):10840-108… [cited by applicant]